Carlo Torti

Background: The relationship between diet and body composition in people with HIV (PWH) is still not well defined. Therefore, our primary objective was to assess the association between Mediterranean diet (MD) adherence and body composition measured by whole-body dual-energy X-ray absorptiometry (DXA). Secondly, we aimed to assess differences between people living in the north (Padua, Veneto Region, Italy) vs. those living in the south of Italy (Catanzaro, Calabria Region, Italy) and with respect to ethnicity. Methods: In this cross-sectional study, adults with HIV with a confirmed virological suppression were enrolled at two Italian HIV clinics. MD adherence was assessed using the validated MedDiet Score, with high adherence being defined as a score ≥ 25. All participants underwent whole-body DXA. Anthropometric and DXA-derived measures were compared between people with high vs. low adherence to MD, and multivariable linear regression adjusted for age, sex, and CD4⁺ count at nadir was performed. Results: Among 130 participants (81.5% male; median age 57 years), 105 (80.8%) showed high MD adherence. High adherence to MD was more common among participants from Southern Italy than among those from Northern Italy and was associated with Caucasian ethnicity, higher education, higher CD4⁺ count and CD4/CD8 ratio, and a lower prevalence of obesity and neurological disorders. DXA analyses showed lower total and trunk fat mass and higher lumbar spine bone mineral density in highly adherent individuals. After adjustment, high MD adherence remained independently associated with lower BMI (β −5.3, 95% CI −7.3 to −3.4; p < 0.001). Conclusions: In ageing PWH, high MD adherence was associated with a more favourable clinical profile and healthier body composition, particularly lower central adiposity and BMI. Prospective and interventional studies are needed to clarify the role of this type of diet in PWH.

Achieving international accreditation standards, including those defined by the Joint Commission International (JCI), requires strong infection prevention

Background/Objectives: Syphilis during pregnancy can be easily missed with potential severe outcomes of the newborns, including congenital syphilis (CS). We report the neonatal outcomes of a cohort of mothers with syphilis during pregnancy. Methods: a retrospective cohort study in a referral university hospital in Rome, enrolling mother/newborn couples followed up from 2016 to 2023 by a multidisciplinary team including infectious disease specialists, obstetricians, microbiologists, neonatologists and pediatricians. Primary outcome was the assessment of risk factors for development of congenital syphilis (CS) in the newborns. Results: Fifty-three pregnant women (median age 34, IQR 29–37 years) with documented syphilis in pregnancy have been included in this study. 50/52 (96.2%) were treated during pregnancy, and forty of them (80%) received adequate treatment. Fifty-three newborns were born from mothers with syphilis during pregnancy (female 25/48, 52.1%). Four newborns were classified as CS (7.5%), and two newborns as probable CS (3.8%). Newborns with CS were born more frequently from mothers treated inadequately (p 0.02), had higher probability of neonatal intensive care unit admission (p < 0.001), had a higher Venereal Disease Research Laboratory (VDRL) titer (p 0.076), higher ALT (p 0.005). Univariate logistic regression conducted on the development of CS showed an adequate treatment as a protective factor (OR 0.03; 95% CI: 0.002; 0.31; p = 0.002), while later weeks of pregnancy for the beginning of treatment as a risk factor (OR 1.24; 95% CI: 1.02; 1.51; p = 0.026). Conclusions: Syphilis still represents a potential problem for women of childbearing age and their newborns, even in a high-income setting, making congenital syphilis far from being eradicated in Italy. Moreover, adequate and early treatment should be provided to avoid negative consequences to the newborns.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, responsible for Coronavirus Disease 2019 (COVID-19), exhibits a spectrum of clinical manifestations, ranging from asymptomatic to severe pulmonary dysfunction or death. The variability in COVID-19 severity has largely been attributed to the host’s genetic characteristics, suggesting a polygenic genetic architecture, without significant strong evidence of sex-related genetic differences. In this Italian retrospective case–control study, we investigated the association between COVID-19 severity (severe vs. asymptomatic/oligosymptomatic healed individuals) and HLA gene variants, analyzed by next-generation sequencing (NGS). We identified significant HLA alleles (according to the conventional nomenclature), SNPs and haplotypes in the HLA-B, -C, -F, -DQA1, -DRB1, and -DRB5 genes associated with COVID-19 severity. Interestingly, these variants showed biological sex-related effects. Also, we identified specific haplotypes associated with COVID-19 severity that are shared by different conventional HLA alleles, indicated here as “super-haplotypes”. These haplotypes had a biological sex-specific impact on disease severity and markedly increased the risk of severe COVID-19 compared to the conventional HLA alleles (odds ratio of up to 15). Our data suggest that the revision of the current HLA nomenclature may help to identify variants with a stronger effect on disease susceptibility and that association studies could benefit from the stratification of patients by biological sex. If replicated in other disease models, these findings could help to define the functional diversity in immune response between sexes, also based on the HLA system. Finally, due to the global pandemic’s mortality rate, we hypothesize here that SARS-CoV-2 may have acted as a natural selection trigger, leading to a drift in HLA allelic frequencies in the general population.

Introduction Sexually transmitted diseases (STDs) are a major cause of long-term disability. Urethral discharge syndrome (UDS), abnormal vaginal discharge (AVD) and genital ulcer disease (GUD) are very common in low-income and middle-income countries (LMICs), where, due to lack of resources, these infections are managed according to a syndromic approach. Although microbiological diagnosis using nuclear acid amplification tests (NAAT) is already a standard to prescribe targeted treatments in industrialised countries, no randomised clinical trials have been conducted to evaluate clinical usefulness and acceptability of NAAT in comparison with syndromic approach in LMICs. The results of this study could inform diagnostic guidelines since they may suggest an update of the current recommendation if microbiological diagnosis using NAAT in the management of STD is demonstrated to be both useful and acceptable in an LMIC context. Methods and analysis The primary objective of this randomised, open-label trial is to evaluate the clinical usefulness of a NAAT and its acceptability in comparison with a clinical syndromic approach and to explore whether this test could replace the syndromic approach in the management of STDs at a national referral hospital in Uganda. 220 patients presenting to the STD clinic at Mulago Hospital in Kampala, Uganda with AVD, UDS or GUD will be randomised to either standard of care (syndromic management) or NAAT-based treatment with a 1:1 ratio. All the patients will be asked to return after 2 or 3 weeks for a control visit. Primary outcome will be therapeutic appropriateness. Ethics and dissemination This trial was approved by the Mulago Hospital Research and Ethical Committee (MHREC2023-97) and the Uganda National Council for Science and Technology (HS31000ES). Patients will give informed consent to participate before taking part in the study. Results will be published in peer-reviewed journals in open-access formats and data made available in anonymised form. Trial registration number NCT05994495.

Cutaneous bacillary angiomatosis (cBA) is a vascular proliferative disorder due to Bartonella spp. that mostly affects people living with HIV (PLWH), transplanted patients and those taking immunosuppressive drugs. Since cBA is mostly related to these major immunocompromising conditions (i.e., T-cell count impairment), it is considered rare in relatively immunocompetent patients and could be underdiagnosed in them. Moreover, antimicrobial treatment in this population has not been previously investigated. We searched the databases PubMed, Google Scholar, Scopus, OpenAIRE and ScienceDirect by screening articles whose title included the keywords “bacillary” AND “angiomatosis” and included case reports about patients not suffering from major immunocompromising conditions to provide insights about antibiotic treatments and their duration. Twenty-two cases of cBA not related to major immunocompromising conditions were retrieved. Antibiotic treatment duration was shorter in patients with single cBA lesion than in patients with multiple lesions, including in most cases macrolides and tetracyclines. cBA is an emerging manifestation of Bartonella spp. infection in people not suffering from major immunocompromising conditions. Until evidence-based guidelines are available, molecular tests together with severity and extension of the disease can be useful to personalize the type of treatment and its duration.